XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Data
 9 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
Segment Data Segment DataThe Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses. Revenues and operating income from the Diabetes Care business prior to its spin-off are included in Income from Discontinued Operations, Net of Tax. See Note 2 for further information.
Revenues by segment, organizational unit and geographical areas for the three and nine-month periods are detailed below. The Company has no material intersegment revenues.
Three Months Ended June 30,
(Millions of dollars)20232022
United StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions$628 $459 $1,086 $621 $439 $1,061 
Medication Management Solutions587 167 754 463 144 607 
Pharmaceutical Systems186 408 594 135 388 523 
Total segment revenues$1,400 $1,033 $2,434 $1,219 $971 $2,191 
Life Sciences
Integrated Diagnostic Solutions$398 $460 $858 $499 $461 $961 
Biosciences148 220 368 147 201 348 
Total segment revenues$546 $680 $1,226 $646 $663 $1,309 
Interventional
Surgery$298 $90 $388 $274 $77 $352 
Peripheral Intervention256 225 481 255 208 463 
Urology and Critical Care272 77 349 248 79 326 
Total segment revenues$826 $392 $1,218 $777 $364 $1,142 
Total Company revenues from continuing operations$2,772 $2,106 $4,878 $2,643 $1,998 $4,641 
Nine Months Ended June 30,
(Millions of dollars)20232022
United StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions$1,863 $1,332 $3,195 $1,831 $1,375 $3,207 
Medication Management Solutions1,701 483 2,184 1,408 430 1,838 
Pharmaceutical Systems478 1,092 1,570 363 1,057 1,420 
Total segment revenues$4,042 $2,907 $6,949 $3,602 $2,863 $6,465 
Life Sciences
Integrated Diagnostic Solutions$1,327 $1,371 $2,699 $1,732 $1,524 $3,255 
Biosciences444 660 1,104 405 617 1,022 
Total segment revenues$1,772 $2,031 $3,803 $2,136 $2,140 $4,277 
Interventional
Surgery$880 $252 $1,131 $824 $229 $1,053 
Peripheral Intervention748 635 1,383 712 615 1,327 
Urology and Critical Care794 225 1,019 740 247 987 
Total segment revenues$2,421 $1,112 $3,533 $2,276 $1,091 $3,367 
Total Company revenues from continuing operations$8,235 $6,050 $14,285 $8,014 $6,095 $14,109 
Segment income for the three and nine-month periods was as follows:
 Three Months Ended
June 30,		Nine Months Ended
June 30,
(Millions of dollars)2023202220232022
Income from Continuing Operations Before Income Taxes
Medical (a)$588 $573 $1,783 $1,587 
Life Sciences343 414 1,171 1,366 
Interventional323 293 922 826 
Total Segment Operating Income1,254 1,280 3,875 3,778 
Acquisition-related integration and restructuring expense(70)(36)(175)(99)
Net interest expense (95)(94)(299)(285)
Other unallocated items (b)(618)(728)(1,920)(1,932)
Total Income from Continuing Operations Before Income Taxes$471 $421 $1,481 $1,463 
(a)The amounts include charges recorded to Cost of products sold of $90 million for the three and nine months ended June 30, 2023 and $41 million for the nine months ended June 30, 2022 to adjust estimated future product remediation costs. The amount for the nine months ended June 30, 2022 also includes a charge of $54 million recorded to Cost of products sold to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit.
(b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.